Search

Semih U Tareen

from Seattle, WA
Age ~48
Get Report
Related to:
Zeynep Tareen, 48Inam U Tareen, 80Ayse E TareenYasemin Tareen, 45
Connected to:
Fatima Tareen, 63Khurram A Tareen, 72Yasmeen K Tareen, 64John P Tareila, 39Saqr H Tarek, 77Gebru Tareke, 84Diana C Tarello, 34Lupe Tarelo, 31Pouran Taremi, 60Quayde Taren, 32

Semih Tareen Phones & Addresses

  • 4316 Greenwood Ave N, Seattle, WA 98103
    • s
  • 4316 Greenwood Ave N #A, Seattle, WA 98103
  • Mountlake Terrace, WA
  • 6841 Walnut Bend Rd, Indianapolis, IN 46254 (317) 295-9256
  • 7054 Chesterton Cir, Indianapolis, IN 46237 (317) 883-1576
  • Lynnwood, WA
  • 3703 223Rd St SW, Mountlake Terrace, WA 98043 (425) 776-8610

Resumes

Resumes

Semih Tareen Photo 1

Senior Director

View page
Location:
307 Westlake Ave north, Seattle, WA 98109
Industry:
Biotechnology
Work:
Juno Therapeutics, Inc. Jun 8, 2014 - Dec 3, 2018
Director
Sana Biotechnology Jun 8, 2014 - Dec 3, 2018
Senior Director
Black Sunday Productions Jun 8, 2014 - Dec 3, 2018
President and Chief Executive Officer
Immune Design Jul 2010 - Jun 2014
Scientist Ii
Fred Hutch Sep 2005 - Jun 2010
Graduate Research Assistant
Education:
University of Washington 2005 - 2010
Doctorates, Doctor of Philosophy, Biology, Philosophy University of Washington 1995 - 1998
Bachelors, Bachelor of Science, Microbiology Seattle Film Institute
Skills:
Viral Vectors
Cancer Immunotherapy
Pre Clinical Studies
Drug Discovery
Molecular Biology
Immunology
Cell Biology
Cell Culture
Assay Development
Biotechnology
Flow Cytometry
Western Blotting
Tissue Culture
Infectious Diseases
Cancer Research
Vaccines
Virology
Glp
Microbiology
Leadership
Team Building
Management
Program Management
Team Leadership
Cmc Development
Cmc
Fda
Immunotherapy
Strategic Planning
Strategy
Cell Therapy
Film Scoring
Film Production
Independent Film
Languages:
Turkish
Semih Tareen Photo 2

Entertainment Professional

View page
Location:
Greater Seattle Area
Industry:
Entertainment

Publications

Us Patents

Methods Useful For Generating Highly Mannosylated Pseudotyped Lentiviral Vector Particles Comprising A Vpx Protein

View page
US Patent:
8323662, Dec 4, 2012
Filed:
Mar 30, 2012
Appl. No.:
13/436472
Inventors:
Christopher James Nicolai - Seattle WA, US
Semih Ullah Tareen - Seattle WA, US
Assignee:
Immune Design Corp. - Seattle WA
International Classification:
A61K 39/12
A61K 39/21
C12N 15/00
US Classification:
4241991, 4242081, 4353201
Abstract:
Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided. More specifically, methods for generating such materials include culturing in a culture medium including kifunensine a virus packaging cell with a lentiviral vector genome including a polynucleotide encoding an exogenous antigen, a polynucleotide encoding a Sindbis E2 glycoprotein that preferentially binds dendritic cells expressing DC-SIGN, and a polynucleotide encoding a Vpx protein or a Vpr protein that retains SAMHD1-inhibiting activity, followed by isolating a pseudotyped lentiviral vector particle that preferentially binds dendritic cells expressing DC-SIGN.

Methods, Kits, Agents And Apparatuses For Transduction

View page
US Patent:
20220243223, Aug 4, 2022
Filed:
Jan 18, 2022
Appl. No.:
17/578425
Inventors:
- Munich, DE
Semih U. TAREEN - Seattle WA, US
Assignee:
Juno Therapeutics GmbH - Munich
International Classification:
C12N 15/86
C07K 14/315
C07K 14/725
C07K 16/28
C12N 5/0783
Abstract:
Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.

Chimeric Antigen Receptors Specific For G Protein-Coupled Receptor Class C Group 5 Member D (Gprc5D)

View page
US Patent:
20210393689, Dec 23, 2021
Filed:
Oct 31, 2019
Appl. No.:
17/290060
Inventors:
- Seattle WA, US
- New York NY, US
Cyr DE IMUS - Seattle WA, US
Kimberly HARRINGTON - Seattle WA, US
Jon JONES - Seattle WA, US
Aye CHEN - Seattle WA, US
Semih TAREEN - Seattle WA, US
Erik HESS - Seattle WA, US
Stefan PONKO - Seattle WA, US
Audrey OLSHEFSKY - Seattle WA, US
Carlos FERNANDEZ DE LARREA - Barcelona, ES
Renier BRENTJENS - New York NY, US
Assignee:
Juno Therapeutics, Inc. - Seattle WA
Memorial Sloan Kettering Cancer Center - New York NY
International Classification:
A61K 35/17
C07K 16/28
C07K 16/30
A61P 35/00
Abstract:
Provided are chimeric antigen receptors (CARs), which contain antibody portions specific to G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D) and polynucleotides that encode CARs specific for GPRC5D. The disclosure further relates to genetically engineered cells, containing such GPRCSD-binding receptors, and uses thereof in adoptive cell therapy.

Methods For Treatment Using Chimeric Antigen Receptors Specific For B-Cell Maturation Antigen

View page
US Patent:
20210393690, Dec 23, 2021
Filed:
Oct 31, 2019
Appl. No.:
17/290065
Inventors:
- Seattle MA, US
- New York NY, US
Semih TAREEN - Seattle WA, US
Aye CHEN - Seattle WA, US
Cyr DE IMUS - Seattle WA, US
Erik HESS - Seattle WA, US
Audrey OLSHEFSKY - Seattle WA, US
Stefan PONKO - Seattle WA, US
Mariana Cota STIRNER - Seattle WA, US
Assignee:
Juno Therapeutics, Inc. - Seattle WA
Memorial Sloan Kettering Cancer Center - New York NY
International Classification:
A61K 35/17
A61P 35/00
C07K 14/705
C07K 14/725
C07K 16/28
Abstract:
Provided herein are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain plasma cell malignancy. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM). Also provided are genetically engineered cells containing such BCMA-binding receptors for uses in adoptive cell therapy.

Chimeric Antigen Receptors Specific For B-Cell Maturation Antigen And Encoding Polynucleotides

View page
US Patent:
20210324100, Oct 21, 2021
Filed:
Jun 21, 2021
Appl. No.:
17/353648
Inventors:
- Seattle WA, US
- New York NY, US
Rupesh AMIN - Seattle WA, US
Aye CHEN - Seattle WA, US
Kimberly HARRINGTON - Seattle WA, US
Collin HAUSKINS - Seattle WA, US
Erik HESS - Seattle WA, US
Cyr DE IMUS - Seattle WA, US
Jon JONES - Seattle WA, US
Audrey OLSHEFSKY - Seattle WA, US
Stefan PONKO - Seattle WA, US
Ruth SALMON - Seattle WA, US
Semih TAREEN - Seattle WA, US
Rebecca WU - Seattle WA, US
Yan CHEN - Seattle WA, US
Steven M. SHAMAH - Seattle WA, US
Csaba PAZMANY - Seattle WA, US
Jui DUTTA-SIMMONS - Seattle WA, US
Mariana Cota STIRNER - Seattle WA, US
Melissa WORKS - Seattle WA, US
Assignee:
Juno Therapeutics, Inc. - Seattle WA
Memorial Sloan Kettering Cancer Center - New York NY
International Classification:
C07K 16/28
A61K 35/17
C07K 14/725
A61P 35/00
A61K 39/395
C07K 14/705
C12Q 1/6848
Abstract:
Provided herein are chimeric receptors, such as chimeric antigen receptors (CARs), comprising BCMA-binding molecules, such as anti-BCMA antibodies and antigen-binding fragments thereof, such as heavy chain variable (V) regions and single-chain antibody fragments, and encoding polynucleotides. In some embodiments, the anti-BCMA chimeric receptors specifically bind to BCMA. Among the anti-BCMA-binding molecules are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs and uses thereof such as in adoptive cell therapy.

Materials And Methods For Producing Improved Lentiviral Vector Particles

View page
US Patent:
20200030423, Jan 30, 2020
Filed:
Jul 16, 2019
Appl. No.:
16/513263
Inventors:
- Seattle WA, US
Semih U. Tareen - Seattle WA, US
International Classification:
A61K 39/00
C12N 7/00
A61K 39/12
A61K 47/42
A61K 39/21
Abstract:
Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided.

Methods, Kits, Agents And Apparatuses For Transduction

View page
US Patent:
20200017880, Jan 16, 2020
Filed:
Oct 20, 2016
Appl. No.:
15/770177
Inventors:
- Munich, DE
Semih U. TAREEN - Seattle WA, US
Assignee:
Juno Therapeutics GmbH - Munich
International Classification:
C12N 15/86
C12N 5/0783
C07K 14/725
C07K 16/28
C07K 14/315
Abstract:
Provided herein are methods for transducing a plurality of cells in a composition of cells, such as a population of lymphocytes, containing viral particles. In some aspects, provided methods and reagents for the transduction of cell populations involve binding of agents to a molecule on the surface of the cells. In some cases, the reagents are multimerization reagents and the one or more agents are multimerized by reversibly binding to the reagent. In some aspects, the multimerized agent can provide for transduction and/or expansion or proliferation or other stimulation of a population of cells, and then such agents can be removed by disruption of the reversible bond. Also provided are compositions, apparatus and methods of use thereof.

Production Of Engineered Cells For Adoptive Cell Therapy

View page
US Patent:
20190350978, Nov 21, 2019
Filed:
Dec 5, 2017
Appl. No.:
16/465140
Inventors:
- Seattle WA, US
Semih U. TAREEN - Seattle WA, US
Assignee:
Juno Therapeutics, Inc. - Seattle WA
International Classification:
A61K 35/17
C12N 5/0783
C07K 14/725
C07K 14/47
Abstract:
Provided are methods for genetically engineering cells, including cells for use in connection with genetic engineering. In some embodiments, the provided methods including transduction of cells by incubation with a retroviral vector particle, e.g. lentiviral vector, in which, prior to the incubation, the cells have not been incubated with an activating or stimulating agent, such as have not been incubated with anti-CD3/anti-CD28 antibodies and/or one or more recombinant cytokines. In some embodiments, such methods result in features related to shortening or improving the process for genetically engineering cells. Also provided are resulting cells, transduced with a recombinant or heterologous gene, such as one encoding a chimeric receptor such as a chimeric antigen receptor, or other recombinant antigen receptor such as a transgenic T cell receptor, and compositions thereof. In some embodiments, the provided cells and compositions can be used in methods of adoptive immunotherapy.
Control profile
Semih U Tareen from Seattle, WA, age ~48 Get Report